Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial.
Biau J, Lopez L, Thivat E, Casile M, Millardet C, Saroul N, Pham-Dang N, Molnar I, Bourhis J, Lapeyre M. Biau J, et al. Among authors: millardet c. Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.007. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36466746 Free PMC article.
A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, Pereira B, Durando X, Bourhis J, Lapeyre M. Biau J, et al. Among authors: millardet c. BMC Cancer. 2020 Aug 5;20(1):730. doi: 10.1186/s12885-020-07231-3. BMC Cancer. 2020. PMID: 32758188 Free PMC article. Clinical Trial.
[Description of the GORTEC 2017-03 study: Postoperative stereotactic radiotherapy for early stage oropharyngeal and oral cavity cancer with high risk margin (PHRC-K-16-164)].
Biau J, Miroir J, Millardet C, Saroul N, Pham-Dang N, Racadot S, Huguet F, Kwiatkowski F, Pereira B, Bourhis J, Lapeyre M. Biau J, et al. Among authors: millardet c. Cancer Radiother. 2017 Oct;21(6-7):527-532. doi: 10.1016/j.canrad.2017.07.033. Epub 2017 Aug 31. Cancer Radiother. 2017. PMID: 28865970 Clinical Trial. French.
Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT.
Bouchet F, Geworski L, Knoop BO, Ferrer L, Barriolo-Riedinger A, Millardet C, Fourcade M, Martineau A, Belly-Poinsignon A, Djoumessi F, Tendero K, Keros L, Montoya F, Mesleard C, Martin AL, Lacoeuille F, Couturier O. Bouchet F, et al. Among authors: millardet c. PLoS One. 2013;8(3):e58152. doi: 10.1371/journal.pone.0058152. Epub 2013 Mar 13. PLoS One. 2013. PMID: 23516443 Free PMC article.
Proficiency of PCR in hospital settings for nonculture diagnosis of invasive meningococcal infections.
Hong E, Barraud O, Bidet P, Bingen E, Blondiaux N, Bonacorsi S, Burucoa C, Carrer A, Fortineau N, Couetdic G, Courcol R, Garnier F, Hery-Arnaud G, Lanotte P, Le Bars H, Legrand-Quillien MC, Lemée L, Mereghetti L, Millardet C, Minet J, Plouzeau-Jayle C, Pons JL, Schneider J, Taha MK. Hong E, et al. Among authors: millardet c. Clin Lab. 2012;58(3-4):343-6. Clin Lab. 2012. PMID: 22582511